Efficacy and Dose-Response Study of Enhanced External Counterpulsation on Blood Pressure in Patients with Prehypertension or Stage 1 Primary Hypertension: A Multicenter, Two-Phase, Double-Blind, Randomized Controlled Trial

INTERVENTION: Experimental group:EECP 60min/session, 3‐5sessions/wk, 35 sessions in total;Control group:sham EECP 60min/session,3‐5sessions/wk, 35 sessions in total; CONDITION: Prehypertension or stage 1 primary hypertension PRIMARY OUTCOME: The difference in systolic blood pressure (measured by 24‐hour ambulatory blood pressure) between the experimental group and the control group after 35 interve; SECONDARY OUTCOME: home blood pressure;office blood pressure;daytime mean blood pressure;nighttime mean blood pressure;vascular endothelial function;Pulse wave velocity;Ankle‐brachial index;cardiac output;cardiac index;Peripheral vascular resistance;Peripheral vascular resistance index;quality of life; INCLUSION CRITERIA: 1. Age between 18 and 64 years old; 2. According to the 2024 China Hypertension Clinical Practice Guidelines [2], patients with clearly diagnosed non‐high‐risk prehypertension (A. systolic blood pressure 130 139mmHg and/or diastolic blood pressure 80 89mmHg; B. with 0 2 cardiovascular risk factors), or patients with stage 1 primary hypertension (systolic blood pressure 140 159mmHg and/or diastolic blood pressure 89 99mmHg) who refuse to use antihypertensive drugs or whose blood pressure has not reached the target level after using antihypertensive drugs for at least one month (systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >=90 mmHg). 3.No history of EECP within the past 6 months; 4.Sign the informed consent form.